Management of hyperuricemia in gout: focus on febuxostat
Authors:
- Mark ReindersMRMark Reinders
- JansenJAJansen
Open Access
- 1 January 2010
- journal article
- review article
- Published by Taylor & Francis in Clinical Interventions in Aging
- Vol. 5, 7-18
Abstract
Peer reviewed article authored by (Mattheus K Reinders, Tim L Th A Jansen). Read article or submit your manuscript for publishing.Keywords
This publication has 70 references indexed in Scilit:
- Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinolAnnals of the Rheumatic Diseases, 2009
- A Benefit-Risk Assessment of Benzbromarone in the Treatment of GoutDrug Safety, 2008
- Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjectsBritish Journal of Clinical Pharmacology, 2007
- Effectiveness of interventions for the treatment of acute and prevention of recurrent gout—a systematic reviewRheumatology, 2006
- Pharmacokinetics and Pharmacodynamics of Febuxostat, a New Non-purine Selective Inhibitor of Xanthine Oxidase in Subjects with Renal ImpairmentAmerican Journal of Therapeutics, 2005
- Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.2004
- Benzbromarone withdrawn from the European market: another case of "absence of evidence is evidence of absence"?2004
- Purine-Rich Foods, Dairy and Protein Intake, and the Risk of Gout in MenNew England Journal of Medicine, 2004
- The Management of Hyperuricemia and Gout in Patients with Heart FailureEuropean Journal of Heart Failure, 2002
- Severe allopurinol toxicityThe American Journal of Medicine, 1984